Neuronetics (Nasdaq:STIM) announced that it implemented improved internet connectivity capabilities across its NeuroStar platform. Malvern, Pennsylvania-based Neuronetics develops products aimed at improving the life of patients with neuro health disorders. Its latest updates to NeuroStar particularly improve connectivity for providers with restricted networks. NeuroStar, a non-drug, non-invasive treatment can improve the quality of life for […]
Neuronetics
Neuronetics shares rise on Street-beating Q3 results
Neuronetics (NSDQ:STIM) this week posted third-quarter results that beat the consensus on Wall Street. The Malvern, Pennsylvania-based psychiatric disorder treatment developer reported a net loss of $7.6 million, or -28¢ per share, on sales of $16.5 million for the three months ended Sept. 30, on sales growth of 19.56% compared with Q3 2021. Earnings per share […]
FDA clears Neuronetics’ motor threshold detection tech
Neuronetics (Nasdaq:STIM) announced today that it received FDA 510(k) clearance for its D-Tect MT accessory for the NeuroStar platform. Malvern, Pennsylvania-based Neuronetics designed its D-Tect accessory to simplify the motor threshold (MT) determination for physicians. According to a news release, the now FDA-cleared technology gives clinicians a way to determine MT by visually reporting the […]
Neuronetics stock rises on Street-beating Q2
Neuronetics (Nasdaq:STIM) shares ticked up today on second-quarter results that beat the consensus forecast. The Malvern, Pennsylvania-based company posted losses of $10.4 million, or 39¢ per share, on sales of $16.3 million for the three months ended June 30, 2022, for a bottom-line deeper into the red on sales growth of nearly 15%. Neuronetics’ losses […]
Neuronetics inks deal with Alleviant to supply NeuroStar to mental health clinics
Neuronetics (Nasdaq:STIM) announced today that it entered into a commercial partnership with Alleviant Health Centers. Under the agreement, Malvern, Pennsylvania-based Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to Alleviant and its clinics. According to a news release, an initial six NeuroStar advanced therapy systems — Neuronetics’ non-drug, non-invasive treatment […]
FDA clears Neuronetics’ therapy for anxious depression
Neuronetics (Nasdaq:STIM) announced today that the FDA cleared a new indication for its transcranial magnetic stimulation (TMS) system. The new indication for the NeuroStar advanced therapy for mental health allows the system to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression. NeuroStar is a non-drug, […]
Neuronetics ticks up before hours on mixed-bag Q1 results
Neuronetics (NSDQ:STIM) posted first-quarter results today that beat the revenue consensus on Wall Street and matched on earnings. The Malvern, Pa.-based company reported losses of -$7.9 million, or -31¢ per share, on sales of $12.3 million for the three months ended March 31, 2021, for a sales growth of 7.08% compared with Q1 2020. Earnings per […]
Neuronetics up on Street-beating Q3 results despite losses
Neuronetics (NSDQ:STIM) posted third-quarter results today that beat the consensus on Wall Street. The Malvern, Penn.-based company reported losses of $3.4 million, or -18¢ per share, on sales of $12.4 million for the three months ended Sept. 30, for a sales loss of -22.2% compared with Q3 2019. Earnings per share were -18¢, 11¢ ahead of […]
Neuronetics rises on Street-beating Q2
Neuronetics (NSDQ:STIM) shares ticked up today on second-quarter losses that managed to top the consensus forecast. The Malvern, Pa.-based psychiatric disorder treatment developer posted losses of $-7.8 million, or -41¢ per share, on sales of $9.7 million for the three months ended June 30, 2020, for a -9.5% bottom-line slide on a sales decline of -41.2%. […]
Neuronetics slides on missed Q1 projections, withdraws 2020 guidance
Neuronetics (NSDQ:STIM) posted first-quarter results that missed the consensus forecast on Wall Street. The Malvern, Penn.-based company reported losses of $12.6 million, or -68¢, on sales of $11.5 million for the three months ended March 31, for a bottom-line sales loss of -9.8% compared with Q1 2019. Earnings per share were -68¢, 16¢ behind The Street, […]
Neuronetics, Obalon Therapeutics get PPP loans
Neuronetics (NSDQ:STIM) and Obalon Therapeutics (NSDQ:OBLN) are the latest companies to announce that they entered into loans under the Paycheck Protection Program (PPP). The U.S. Small Business Association administers the PPP as part of the Coronavirus Aid, Relief and Economic Security (CARES) Act. Under the PPP, 75% of the loan proceeds must be used for payroll purposes, […]
